Overview

A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors

Status:
RECRUITING

Trial end date:
2026-08-01

Target enrollment:

Participant gender:

Summary

This study is an open, multicenter, dose-escalation and expansion-enrollment nonrandomized phase I clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary efficacy of BL-M17D1 in locally advanced or metastatic HER2 positive/lower expression gastrointestinal cancer and other solid tumors.

Phase:

PHASE1

Details

Lead Sponsor:

Sichuan Baili Pharmaceutical Co., Ltd.

Collaborator:

Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.